ZUTRIPRO
Peakchlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride
NDAORALSOLUTION
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 35m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZUTRIPRO is a fixed-dose oral solution combining chlorpheniramine maleate (antihistamine), hydrocodone bitartrate (opioid antitussive), and pseudoephedrine hydrochloride (decongestant) for symptomatic relief of cough and upper respiratory symptoms. This combination targets multiple pathways of cold and allergy symptom management in a single formulation. The product is designed for patients requiring coordinated relief of histamine-mediated, cough-reflex, and nasal congestion symptoms.
Peak
Product is at peak commercial stage with moderate competitive pressure (30), suggesting stable but not expanding team dynamics; roles likely focused on maintaining market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZUTRIPRO offers stable, predictable commercial career exposure in a mature symptomatic-relief market with established demand and regulatory clarity. Roles are likely focused on sales optimization, market maintenance, and competitive positioning rather than transformative innovation or launch dynamics.
Brand ManagerProduct Manager
Worked on ZUTRIPRO at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.